Impact of Beta-blocker on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement (B-TAVR)

Summary

This is a multi-centric, open-label, randomized trial to evaluate the safety and efficacy of temporary discontinuation of beta-blocker treatment in patients undergoing transcatheter aortic valve replacement.

Eligibility

Inclusion Criteria:

* Informed Consent must be signed by the subject prior to any study intervention.
* Adult patients (\> 18 years) with severe symptomatic aortic stenosis eligible and scheduled for elective TAVR and are able to give consentand are able to give consent
* Indication for B-blocker therapy with a prior treatment duration of at least 1 month before inclusion.

Exclusion Criteria:

* Emergency or urgent indication for TAVR.
* Hemodynamically unstable patients receiving inotropic medication.
* Prior permanent pacemaker implantation.
* Existing indication for pacemaker implantation.
* Hemodynamic relevant left ventricular outflow tract obstruction.
* Prior intolerance of B-blocker medication.
* Life expectancy \< 1 year.
* Known or suspected non-compliance, drug, or alcohol abuse.
* Inability to give consent, or follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
* Being in a dependent relationship with the trial site
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Previous enrolment into the current study.
* Pregnancy or breast feeding women

Conditions2

Browse More Trials